Free Trial
NASDAQ:XGN

Exagen (XGN) Stock Price, News & Analysis

Exagen logo
$10.94 -0.02 (-0.19%)
As of 01:25 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Exagen Stock (NASDAQ:XGN)

Advanced

Key Stats

Today's Range
$10.84
$11.00
50-Day Range
$7.39
$10.99
52-Week Range
$2.38
$11.17
Volume
71,431 shs
Average Volume
229,906 shs
Market Capitalization
$240.57 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.00
Consensus Rating
Moderate Buy

Company Overview

Exagen Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
77th Percentile Overall Score

XGN MarketRank™: 

Exagen scored higher than 77% of companies evaluated by MarketBeat, and ranked 234th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Exagen has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 8 buy ratings, no hold ratings, and 1 sell rating.

  • Upside/Downside

    The consensus price target for Exagen is close to its current price, suggesting limited near-term upside or downside.

  • Amount of Analyst Coverage

    Exagen has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Exagen's stock forecast and price target.
  • Earnings Growth

    Earnings for Exagen are expected to grow in the coming year, from ($0.88) to ($0.57) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Exagen is -12.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Exagen is -12.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Exagen has a P/B Ratio of 20.25. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Exagen's valuation and earnings.
  • Percentage of Shares Shorted

    4.47% of the float of Exagen has been sold short.
  • Short Interest Ratio / Days to Cover

    Exagen has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Exagen has recently increased by 0.03%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Exagen does not currently pay a dividend.

  • Dividend Growth

    Exagen does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    4.47% of the float of Exagen has been sold short.
  • Short Interest Ratio / Days to Cover

    Exagen has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Exagen has recently increased by 0.03%, indicating that investor sentiment is decreasing.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Exagen this week, compared to 2 articles on an average week.
  • Search Interest

    1 people have searched for XGN on MarketBeat in the last 30 days.
  • MarketBeat Follows

    2 people have added Exagen to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Exagen insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    12.60% of the stock of Exagen is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    75.25% of the stock of Exagen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Exagen's insider trading history.
Receive XGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Exagen and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

XGN Stock News Headlines

Nvidia CEO Makes First Ever Tesla Announcement
While headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $25 trillion AI revolution — one that Nvidia’s CEO himself has called a “multi-trillion-dollar future industry” — and he’s uncovered a little-known stock 168 times smaller than Nvidia that could be positioned to ride this breakthrough.tc pixel
Exagen initiated with a Buy at B. Riley
Beyond The Numbers: 4 Analysts Discuss Exagen Stock
See More Headlines

XGN Stock Analysis - Frequently Asked Questions

Exagen's stock was trading at $4.10 at the start of the year. Since then, XGN shares have increased by 166.7% and is now trading at $10.9350.

Exagen Inc. (NASDAQ:XGN) posted its quarterly earnings results on Tuesday, July, 29th. The company reported ($0.18) EPS for the quarter, meeting the consensus estimate of ($0.18). The business earned $17.20 million during the quarter, compared to analyst estimates of $16.25 million. Exagen had a negative trailing twelve-month return on equity of 130.38% and a negative net margin of 28.85%.
Read the conference call transcript
.

Exagen (XGN) raised $50 million in an IPO on Thursday, September 19th 2019. The company issued 3,300,000 shares at a price of $14.00-$16.00 per share. Cowen, Cantor and William Blair served as the underwriters for the IPO.

Shares of XGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Exagen investors own include Chemours (CC), Ovintiv (OVV), Himax Technologies (HIMX), ImmunoGen (IMGN), Cassava Sciences (SAVA), CNX Resources (CNX) and Ford Motor (F).

Company Calendar

Last Earnings
7/29/2025
Today
10/06/2025
Next Earnings (Estimated)
11/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED PRODUCTS
Sub-Industry
Healthcare
Current Symbol
NASDAQ:XGN
CIK
1274737
Fax
N/A
Employees
220
Year Founded
2002

Price Target and Rating

High Price Target
$15.00
Low Price Target
$10.00
Potential Upside/Downside
+9.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.78
Research Coverage
9 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.89)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$15.11 million
Net Margins
-28.85%
Pretax Margin
-28.76%
Return on Equity
-130.38%
Return on Assets
-34.69%

Debt

Debt-to-Equity Ratio
1.06
Current Ratio
4.95
Quick Ratio
4.95

Sales & Book Value

Annual Sales
$55.64 million
Price / Sales
4.33
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.54 per share
Price / Book
20.30

Miscellaneous

Outstanding Shares
22,000,000
Free Float
19,231,000
Market Cap
$241.12 million
Optionable
Optionable
Beta
1.54

Social Links

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:XGN) was last updated on 10/6/2025 by MarketBeat.com Staff
From Our Partners